Novo Nordisk-NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up

Novo Nordisk A/S (NVO) reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 83 cents. The company had reported earnings of 71 cents per ADR in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues of $12.3 billion increased 30% in the Danish kroner (DKK) and at the constant exchange rate (CER) in the reported quarter. Total revenues surpassed the Zacks Consensus Estimate of$ 11.3 billio ...